Published on Dec 27, 2011 by Edgar Snyder

FDA Alert: Multaq Linked to Serious Heart Problems

Multaq new heart warning

The U.S. Food and Drug Administration (FDA) released the results of its most recent safety review of the heart drug Multaq. In its review, which included studies done by the drug's manufacturer, Sanofi, the FDA found that Multaq is linked to higher rates of heart attack, stroke, and death in certain patients.

Multaq is currently prescribed to patients who have irregular heartbeats, which includes almost 10 percent of those over the age of 80. But as it turns out, the patients who are prescribed Multaq for their abnormal heartbeats are also those who have a greater risk of adverse cardiovascular events.

Federal health officials have issued a new warning label for the drug which highlights the increased risk of heart-related complications in patients who have abnormal heart rhythms. Multaq already carries the most serious type of warning because the drug can cause severe complications in people with recent heart failure.

For more information on dangerous drugs please visit our firm's website.

“FDA Drug Safety Communication: Review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events.” U.S. Food and Drug Administration. December 19, 2011.
Free Case Review
First Name
Last Name
Briefly describe your injuries